PR Newswire Clinical TrialsOriginal article
HUYABIO International Announces Pivotal Data for HBI-8000 in Advanced Melanoma Selected for Late-Breaking Presentation at ESMO Congress 2026
Phase 3positiveHBI-8000nivolumabPositive
AI Analysis
Summary
HUYABIO International announced positive Phase 3 data for HBI-8000 combined with nivolumab showing statistically significant improvement in median progression-free survival in advanced melanoma patients. The data will be presented as a late-breaking oral presentation at ESMO Congress 2026.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Statistically significant improvement in median progression-free survival in advanced melanoma patients when HBI-8000 was combined with nivolumab vs immunotherapy alone
Importance:7/10
Sentiment:
0.85
Phase 3 DataMelanomaCombination TherapyProgression-Free SurvivalESMO Congress 2026Positive Topline Results
Read the original article
Published by PR Newswire Clinical Trials on September 29, 2026 12:30 PM